Hongtu Wu1, Xian Ding1, Deyu Zhao2, Yong Liang3, Wei Ji4. 1. 1 Department of Pediatrics, Huai'an Second People's Hospital/The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu Province, PR China. 2. 2 Department of Respiratory Medicine, The Affiliated Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, PR China. 3. 3 Central Laboratory of Huai'an Second People's Hospital/the Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu Province, PR China. 4. 4 Department of Respiratory Medicine, The Affiliated Children's Hospital of Suzhou University, Suzhou, Jiangsu Province, PR China.
Abstract
OBJECTIVE: To study the effect of the leukotriene receptor agonist montelukast combined with methylprednisolone on inflammatory response and peripheral blood lymphocyte subset content in children with mycoplasma pneumonia. METHODS:Seventy-four children were enrolled and randomly divided into a standard treatment group and a montelukast plus methylprednisolone group. Serum levels of inflammatory cytokines and corresponding cytokines of T lymphocyte subsets were measured, and peripheral blood was collected to determine the T cell subset content. RESULTS: At 3 days and 7 days after treatment, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly decreased in both groups, while serum IL-4and TGF-β levels and peripheral blood Treg and Th2 content were significantly increased. However, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly lower while serum IL-4and TGF-β levels and peripheral blood Treg and Th2 content were significantly higher in the montelukast plus methylprednisolone group compared with the control group. CONCLUSION:Montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia can inhibit inflammatory responses and regulate levels of Th1/Th2 and Th17/Treg cells.
RCT Entities:
OBJECTIVE: To study the effect of the leukotriene receptor agonist montelukast combined with methylprednisolone on inflammatory response and peripheral blood lymphocyte subset content in children with mycoplasma pneumonia. METHODS: Seventy-four children were enrolled and randomly divided into a standard treatment group and a montelukast plus methylprednisolone group. Serum levels of inflammatory cytokines and corresponding cytokines of T lymphocyte subsets were measured, and peripheral blood was collected to determine the T cell subset content. RESULTS: At 3 days and 7 days after treatment, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly decreased in both groups, while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly increased. However, serum MCP-1, PCT, ICAM-1, CXCL8, CRP, IFN-γ, and IL-17 levels and peripheral blood Th1 and Th17 content were significantly lower while serum IL-4 and TGF-β levels and peripheral blood Treg and Th2 content were significantly higher in the montelukast plus methylprednisolone group compared with the control group. CONCLUSION:Montelukast combined with methylprednisolone for the treatment of mycoplasma pneumonia can inhibit inflammatory responses and regulate levels of Th1/Th2 and Th17/Treg cells.
Authors: Patrick M Meyer Sauteur; Wendy W J Unger; David Nadal; Christoph Berger; Cornelis Vink; Annemarie M C van Rossum Journal: Front Microbiol Date: 2016-03-23 Impact factor: 5.640
Authors: Ira S Rostevanov; Batya Betesh-Abay; Ahmad Nassar; Elina Rubin; Sarit Uzzan; Jacob Kaplanski; Linoy Biton; Abed N Azab Journal: Front Immunol Date: 2022-09-06 Impact factor: 8.786